SCHEMBL640078

SCHEMBL640078

COc1ccc(S(=O)(=O)n2c(=O)n(C(C(=O)Nc3ccccc3)c3ccccc3)c3cc(Cl)ccc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.46
STAT1 P42224 2/20 0.46
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
KLK7 P49862 3/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 1/20 0.38
MAPK8 P45983 1/20 0.38
ALOX12 P18054 1/20 0.38
AVPR2 P30518 2/20 0.38
GPR27 Q9NS67 2/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
GRIK1 P39086 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639914 0.89 PPARG (0.47) RXFP1PPARGPPARAMEN1KMT2A
SCHEMBL640161 0.87 PKM (0.44) RXFP1PPARGPPARAKMT2AALDH1A1
SCHEMBL640892 0.86 PPARG (0.44) RXFP1PPARGPPARAMEN1KMT2A
SCHEMBL641222 0.86 PPARG (0.44) RXFP1PPARGPPARAMEN1KMT2A
SCHEMBL642810 0.84 PPARG (0.41) RXFP1PPARGPPARAMEN1KMT2A
SCHEMBL641506 0.84 PPARG (0.45) RXFP1PPARGPPARAMEN1KMT2A
SCHEMBL640177 0.84 PPARG (0.41) RXFP1PPARGPPARAMEN1KMT2A
SCHEMBL639656 0.83 PPARG (0.43) RXFP1PPARGPPARAMEN1KMT2A
SCHEMBL641120 0.83 PPARG (0.43) RXFP1PPARGPPARAMEN1KMT2A
SCHEMBL642368 0.83 MEN1 (0.39) RXFP1PPARGPPARAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A RXFP1 206/4885STAT1 2231/4885PPARG 1201/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A RXFP1 206/4885STAT1 2231/4885PPARG 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.